Skip to main content
SN

Sora Neuroscience

Sora Neuroscience develops software that utilizes resting-state fMRI technology to provide insights into brain health, enhancing clinical decision-making for physicians treating neurological disorders. By integrating this technology with existing medical tools, the company aims to improve patient care and facilitate informed choices for families.

Updated 2 months ago

Funding

$1.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Physicians treating neurological disorders often lack comprehensive insights into brain health, hindering clinical decision-making. Traditional diagnostic methods may not fully capture the nuances of brain activity, potentially leading to suboptimal treatment plans and outcomes.

Solution

Sora Neuroscience develops software leveraging resting-state fMRI technology to provide physicians with enhanced insights into brain health. By analyzing brain activity patterns, the software aims to improve clinical decision-making in the treatment of neurological disorders. The company focuses on integrating its technology with existing medical tools, enabling seamless adoption into current clinical workflows. The goal is to empower physicians and patients to make more informed choices, ultimately improving patient care and outcomes.

Target Audience

The primary users are physicians, including neuroradiologists and neurosurgeons, who treat patients with neurological disorders.

Features

  • Utilizes resting-state fMRI technology to analyze brain activity patterns.
  • Provides insights into brain health to aid in the diagnosis and treatment of neurological disorders.
  • Designed for integration with existing medical tools and clinical workflows.
  • Built on neuroscience principles and AI machine learning.
This profile is AI-generated and may contain inaccuracies.